Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
Passage Bio (NASDAQ: PASG), a clinical stage genetic medicines company focusing on neurodegenerative diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's president and CEO, Will Chou, M.D., is scheduled to present on Monday, September 9, 2024, at 7:00 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the Investors & Media section of Passage Bio's website at investors.passagebio.com. For those unable to attend the live event, a replay will be available for 30 days following the presentation.
Passage Bio (NASDAQ: PASG), un'azienda nel settore delle medicine genetiche in fase clinica focalizzata sulle malattie neurodegenerative, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale di Investimenti Globali H.C. Wainwright. Il presidente e CEO dell'azienda, Will Chou, M.D., presenterà il lunedì 9 settembre 2024, alle 7:00 a.m. ET.
Gli investitori e le parti interessate possono accedere a un webcast dal vivo della presentazione attraverso la sezione Investitori & Media del sito web di Passage Bio all'indirizzo investors.passagebio.com. Per coloro che non potranno partecipare all'evento dal vivo, sarà disponibile un replay per 30 giorni dopo la presentazione.
Passage Bio (NASDAQ: PASG), una empresa de medicamentos genéticos en etapa clínica que se centra en las enfermedades neurodegenerativas, ha anunciado su participación en la 26ª Conferencia Anual de Inversiones Globales H.C. Wainwright. El presidente y CEO de la empresa, Will Chou, M.D., está programado para presentar el lunes 9 de septiembre de 2024, a las 7:00 a.m. ET.
Los inversores y las partes interesadas pueden acceder a un webcast en vivo de la presentación a través de la sección de Inversores y Medios en el sitio web de Passage Bio en investors.passagebio.com. Para aquellos que no puedan asistir al evento en vivo, habrá un replay disponible por 30 días después de la presentación.
Passage Bio (NASDAQ: PASG)는 신경퇴행성 질환에 중점을 두고 있는 임상 단계 유전자 의약품 회사로, H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 회사의 사장 겸 CEO인 Will Chou, M.D.가 2024년 9월 9일 월요일, 오전 7:00 ET에 발표할 예정입니다.
투자자 및 관심 있는 분들은 Passage Bio 웹사이트의 투자자 및 미디어 섹션에서 라이브 웹캐스트를 통해 발표를 시청할 수 있습니다. 실시간 이벤트에 참석할 수 없는 경우, 발표 후 30일 동안 재생 가능한 재방송이 제공됩니다.
Passage Bio (NASDAQ: PASG), une société de médicaments génétiques en phase clinique se concentrant sur les maladies neurodégénératives, a annoncé sa participation à la 26ème Conférence Annuelle d'Investissement Global H.C. Wainwright. Le président et CEO de l'entreprise, Will Chou, M.D., doit présenter le lundi 9 septembre 2024, à 7h00 ET.
Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la présentation via la section Investisseurs & Médias du site web de Passage Bio à l'adresse investors.passagebio.com. Pour ceux qui ne pourront pas assister à l'événement en direct, un replay sera disponible pendant 30 jours après la présentation.
Passage Bio (NASDAQ: PASG), ein Unternehmen für genetische Medikamente in der klinischen Phase, das sich auf neurodegenerative Erkrankungen konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Der Präsident und CEO des Unternehmens, Will Chou, M.D., wird am Montag, den 9. September 2024, um 7:00 Uhr ET präsentieren.
Investoren und Interessierte können über den Bereich Investoren & Medien auf der Website von Passage Bio unter investors.passagebio.com auf ein Live-Webcast der Präsentation zugreifen. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird 30 Tage lang ein Replay verfügbar sein nach der Präsentation.
- None.
- None.
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET.
A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.
To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com
Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
mikebeyer@sambrown.com
FAQ
When is Passage Bio (PASG) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Passage Bio (PASG) at the investment conference?
How can investors access Passage Bio's (PASG) presentation at the conference?
How long will the replay of Passage Bio's (PASG) presentation be available?
What is the focus of Passage Bio's (PASG) research and development?
